Electrogastrographic study of the effect of transcatheter arterial chemoembolization on gastric myoelectric activity.
BACKGROUND
Transcatheter arterial chemoembolization (TACE) of the hepatic artery is frequently used in the treatment of inoperable hepatocellular carcinoma (HCC). TACE causes not only effective tumor tissue necrosis in patients with hepatoma but also adverse effects on extrahepatic abdominal organs. There are no published reports on the effect of TACE on the gastric myoelectric activity. In this study, using cutaneous electrogastrography (EGG), we evaluated the effect of TACE on gastric myoelectric activity in patients with HCC.


METHODS
A total of 27 patients (24 men and 3 women, aged 22 to 78 years) with hepatoma, admitted for TACE, were included in this study. Furthermore, 28 patients (24 men and 4 women, aged 26 to 75 years), admitted for diagnostic angiography of the liver, served as the control group. Cutaneous EGG was performed before and after TACE or angiography.


RESULTS
In the TACE group there were significant changes in dominant frequency (DF) and percentages of DF in the defined normal range, bradygastric range, and tachygastric range on post-meal EGG. On fasting EGG, only the dominant frequency and percentages of DF in the bradygastric range changed significantly. However, there was no correlation between the occurrence of nausea/vomiting and the degree of change in the EGG variables, during both fasting and postprandial states. In the control group there were no significant differences in EGG variables before and after angiography.


CONCLUSIONS
TACE can affect gastric myoelectric activity in HCC patients. Nevertheless, the relationship between changes in myoelectric activity and the occurrence of gastrointestinal symptoms needs further investigation.
Chang
C S
CS
Dept. of Internal Medicine, Taichung Veterans General Hospital, Taiwan.
Lien
H C
HC
Yeh
H Z
HZ
Poon
S K
SK
Yang
S S
SS
Chen
G H
GH
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000503:physiopathology / Q000628:therapy*; D016022:Case-Control Studies; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D004568:Electrodiagnosis / Q000379:methods; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016065:Myoelectric Complex, Migrating; D013270:Stomach / Q000503:physiopathology*; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D015251:Epirubicin; D007459:Iodized Oil